Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study
Book here or call us at 020 3319 3637.
This is strong evidence for a specific groupb To view or add a comment, sign in FDA has approved deucravacitinib (Sotyktu) the Treatment of Adults with Active Psoriatic Arthritis based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials
This trend is associated with substantial increases in morbidity and mortality, driven by complications including type 2 diabetes (T2D), metabolic dysfunction-associated steatotic liver disease (MASLD), and cardiovascular disease
What this means for most people, is that if they do not stand to benefit significantly from GLP-1 medication the risks may very well exceed any potential benefits
